JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis)

Slides:

Advertisements

Similar presentations

The genomic region spanning rs shows enhancer activity.

Advertisements

Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from baseline to 12 months follow-up in patients.

Copyright © 2016 McGraw-Hill Education. All rights reserved.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

The landscape of cytokine-producing CD4 T cell populations in the peripheral blood (PB) and in the joints. Venn diagrams show the frequency of overlapping.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

MTX-PG concentrations and hepatotoxicity.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and MTPs ((m) to (p)): grade 0.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Typical findings of osteoarthritis at the hip using routine T1-weighted and T2-weighted MRI. (A) Sixty-three years M, T1FS and T2-weighted sequences showing.

XY plots with regression lines (red) showing the relationship between average (left panel) and peak (right panel) tissue stress at all bone sites for dual-energy.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Foot maps showing the patterns of average tissue stress, peak tissue stress, urate deposition in gout and bone erosion in gout. Foot maps showing the patterns.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Treatments considered ‘Appropriate’ in at least one of the four subphenotypes of knee osteoarthritis.12 Quality of evidence is indicated by: bold=good;

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

Distribution of Tc99m-radiolabelled certolizumab pegol in hands, feet and SIJs 4–5 hours postinjection. Distribution of Tc99m-radiolabelled certolizumab.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

EULAR-defined characteristics describing arthralgia at risk for RA

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Maximum mean (SE) per cent change in serum urate from baseline (Emax) following once-daily oral administration of varying verinurad doses in combination.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom panel), showing joints (A) from no inflammation.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort,

Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as domains for the annual systemic assessment of.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

Bland and Altman plots showing the JSN progression score difference (y axis) against the mean JSN progression scores (x axis) of the two reading methods.

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

MRI, STIR sequence of sacroiliac joints (SIJs): minimal localised signal increase on both sides of the upper part of the left SIJ (arrows), which does.

Route to rheumatology and ILAR classification of A-DS and JIA, plus presenting joints involved in A-DS. Route to rheumatology and ILAR classification of.

Imaging methods of photography, MSUS, X-rays and FOI in evaluating a patient with PsA. Imaging methods of photography, MSUS, X-rays and FOI in evaluating.

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Subject disposition through week 156 of treatment

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed to Ehlers-Danlos Syndromes (EDS)

Classification tree with the selected characteristics.

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

Joint pain location and severity.

Depiction of bone marrow oedema using different techniques

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis) at baseline. JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis) at baseline. JNS, joint space narrowing; PIP2-5, second to fifth proximal interphalangeal joints; MCP1-5, first to fifth metacarpophalangeal joints; CMC3-5, third to fifth carpometacarpal joints; MNA, multangular-navicular joint; CNL, capitate-navicular-lunate joint; RC, radiocarpal joint; IP, first interphalangeal joint of the foot; MTP1-5, first to fifth metatarsophalangeal joints. Yinghe Huo et al. RMD Open 2015;1:e000148 Copyright © BMJ Publishing Group & EULAR. All rights reserved.